A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
K36 Therapeutics, Inc.
AgonOx, Inc.
Eli Lilly and Company
Advanced Accelerator Applications
Endocyte
Poseida Therapeutics, Inc.
Advaxis, Inc.
Aragon Pharmaceuticals, Inc.
IGF Oncology, LLC
sigma-tau i.f.r. S.p.A.
Celldex Therapeutics
Celldex Therapeutics
Merck Sharp & Dohme LLC
Tesaro, Inc.
Pharmacyclics LLC.